{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T07:47:56Z","timestamp":1793778476072,"version":"4.6.1"},"reference-count":127,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,4,22]],"date-time":"2026-04-22T00:00:00Z","timestamp":1776816000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100005202","name":"Muscular Dystrophy Association","doi-asserted-by":"publisher","award":["MDA602798"],"award-info":[{"award-number":["MDA602798"]}],"id":[{"id":"10.13039\/100005202","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000893","name":"Simons Foundation","doi-asserted-by":"publisher","award":["887187"],"award-info":[{"award-number":["887187"]}],"id":[{"id":"10.13039\/100000893","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001288","name":"Parkinson's Foundation Inc","doi-asserted-by":"publisher","award":["PF-IMP-1950"],"award-info":[{"award-number":["PF-IMP-1950"]}],"id":[{"id":"10.13039\/100001288","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000057","name":"National Institute of General Medical Sciences","doi-asserted-by":"publisher","award":["5R01GM141296"],"award-info":[{"award-number":["5R01GM141296"]}],"id":[{"id":"10.13039\/100000057","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000065","name":"National Institute of Neurological Disorders and Stroke","doi-asserted-by":"publisher","award":["1U01NS122102-01A1"],"award-info":[{"award-number":["1U01NS122102-01A1"]}],"id":[{"id":"10.13039\/100000065","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000065","name":"National Institute of Neurological Disorders and Stroke","doi-asserted-by":"publisher","award":["1R01NS123556-01A1"],"award-info":[{"award-number":["1R01NS123556-01A1"]}],"id":[{"id":"10.13039\/100000065","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100013301","name":"Parkinson's Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100013301","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100014943","name":"Sarepta Therapeutics Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100014943","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Therapy"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.ymthe.2026.04.038","type":"journal-article","created":{"date-parts":[[2026,4,24]],"date-time":"2026-04-24T23:31:37Z","timestamp":1777073497000},"page":"4635-4655","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["Treatment of Huntington\u2019s disease with a pan-HTT-targeting CRISPR nuclease"],"prefix":"10.1016","volume":"34","author":[{"given":"Katherine","family":"Tan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniela","family":"Del Bosque Siller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alisha Y.","family":"Xiong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna X.A.","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tristan X.","family":"McCallister","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sreya","family":"Mummadi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luke A.","family":"St John","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tae Kyu","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annika N.","family":"Carrillo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel G.","family":"Renshaw","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard H.","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Colin K.W.","family":"Lim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jack","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher J.","family":"Fields","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael R.","family":"Hayden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6004-9664","authenticated-orcid":false,"given":"Thomas","family":"Gaj","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ymthe.2026.04.038_bib1","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1038\/nrneurol.2014.24","article-title":"Huntington disease: natural history, biomarkers and prospects for therapeutics","volume":"10","author":"Ross","year":"2014","journal-title":"Nat. Rev. Neurol."},{"key":"10.1016\/j.ymthe.2026.04.038_bib2","doi-asserted-by":"crossref","first-page":"2327","DOI":"10.1002\/mds.29228","article-title":"Prevalence and incidence of Huntington's disease: an updated systematic review and meta-analysis","volume":"37","author":"Medina","year":"2022","journal-title":"Mov. Disord."},{"key":"10.1016\/j.ymthe.2026.04.038_bib3","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1002\/mds.25717","article-title":"Multisource ascertainment of Huntington disease in Canada: prevalence and population at risk","volume":"29","author":"Fisher","year":"2014","journal-title":"Mov. Disord."},{"key":"10.1016\/j.ymthe.2026.04.038_bib4","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1186\/1750-1172-5-40","article-title":"Huntington's disease: a clinical review","volume":"5","author":"Roos","year":"2010","journal-title":"Orphanet J. Rare Dis."},{"key":"10.1016\/j.ymthe.2026.04.038_bib5","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1016\/0092-8674(93)90585-E","article-title":"A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes. The Huntington's Disease Collaborative Research Group","volume":"72","year":"1993","journal-title":"Cell"},{"key":"10.1016\/j.ymthe.2026.04.038_bib6","doi-asserted-by":"crossref","first-page":"1990","DOI":"10.1126\/science.277.5334.1990","article-title":"Aggregation of huntingtin in neuronal intranuclear inclusions and dystrophic neurites in brain","volume":"277","author":"Difiglia","year":"1997","journal-title":"Science"},{"key":"10.1016\/j.ymthe.2026.04.038_bib7","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1016\/S0092-8674(00)80514-0","article-title":"Huntingtin-encoded polyglutamine expansions form amyloid-like protein aggregates in vitro and in vivo","volume":"90","author":"Scherzinger","year":"1997","journal-title":"Cell"},{"key":"10.1016\/j.ymthe.2026.04.038_bib8","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1038\/sj.embor.7400250","article-title":"Huntingtin and the molecular pathogenesis of Huntington's disease","volume":"5","author":"Landles","year":"2004","journal-title":"EMBO Rep."},{"key":"10.1016\/j.ymthe.2026.04.038_bib9","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1111\/bpa.12426","article-title":"Huntington's disease (HD): the neuropathology of a multisystem neurodegenerative disorder of the human brain","volume":"26","author":"R\u00fcb","year":"2016","journal-title":"Brain Pathol."},{"key":"10.1016\/j.ymthe.2026.04.038_bib10","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/S0092-8674(00)80623-6","article-title":"Reversal of neuropathology and motor dysfunction in a conditional model of Huntington's disease","volume":"101","author":"Yamamoto","year":"2000","journal-title":"Cell"},{"key":"10.1016\/j.ymthe.2026.04.038_bib11","doi-asserted-by":"crossref","first-page":"9773","DOI":"10.1523\/JNEUROSCI.3183-05.2005","article-title":"Full motor recovery despite striatal neuron loss and formation of irreversible amyloid-like inclusions in a conditional mouse model of Huntington\u2019s disease","volume":"25","author":"D\u00edAz-Hern\u00e1Ndez","year":"2005","journal-title":"J. Neurosci."},{"key":"10.1016\/j.ymthe.2026.04.038_bib12","doi-asserted-by":"crossref","first-page":"5820","DOI":"10.1073\/pnas.0501507102","article-title":"RNA interference improves motor and neuropathological abnormalities in a Huntington's disease mouse model","volume":"102","author":"Harper","year":"2005","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.ymthe.2026.04.038_bib13","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1016\/j.neuron.2012.05.009","article-title":"Sustained therapeutic reversal of Huntington's disease by transient repression of huntingtin synthesis","volume":"74","author":"Kordasiewicz","year":"2012","journal-title":"Neuron"},{"key":"10.1016\/j.ymthe.2026.04.038_bib14","doi-asserted-by":"crossref","DOI":"10.1038\/mtna.2016.7","article-title":"Design, characterization, and lead selection of therapeutic miRNAs targeting huntingtin for development of gene therapy for Huntington's disease","volume":"5","author":"Miniarikova","year":"2016","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"10.1016\/j.ymthe.2026.04.038_bib15","doi-asserted-by":"crossref","first-page":"2152","DOI":"10.1038\/mt.2011.219","article-title":"Preclinical safety of RNAi-mediated HTT suppression in the rhesus macaque as a potential therapy for Huntington's disease","volume":"19","author":"Mcbride","year":"2011","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2026.04.038_bib16","doi-asserted-by":"crossref","first-page":"5868","DOI":"10.1073\/pnas.0801775105","article-title":"Artificial miRNAs mitigate shRNA-mediated toxicity in the brain: implications for the therapeutic development of RNAi","volume":"105","author":"Mcbride","year":"2008","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.ymthe.2026.04.038_bib17","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1038\/s41587-019-0205-0","article-title":"A divalent siRNA chemical scaffold for potent and sustained modulation of gene expression throughout the central nervous system","volume":"37","author":"Alterman","year":"2019","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.ymthe.2026.04.038_bib18","doi-asserted-by":"crossref","first-page":"17204","DOI":"10.1073\/pnas.0708285104","article-title":"Therapeutic silencing of mutant huntingtin with siRNA attenuates striatal and cortical neuropathology and behavioral deficits","volume":"104","author":"Difiglia","year":"2007","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.ymthe.2026.04.038_bib19","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1089\/hum.2013.200","article-title":"Silencing mutant huntingtin by adeno-associated virus-mediated RNA interference ameliorates disease manifestations in the YAC128 mouse model of Huntington's disease","volume":"25","author":"Stanek","year":"2014","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.ymthe.2026.04.038_bib20","doi-asserted-by":"crossref","first-page":"4043","DOI":"10.1093\/brain\/awae266","article-title":"Exon 1-targeting miRNA reduces the pathogenic exon 1 HTT protein in Huntington's disease models","volume":"147","author":"Sogorb-Gonzalez","year":"2024","journal-title":"Brain."},{"key":"10.1016\/j.ymthe.2026.04.038_bib21","doi-asserted-by":"crossref","first-page":"2298","DOI":"10.1093\/brain\/awac458","article-title":"AAV5-miHTT-mediated huntingtin lowering improves brain health in a Huntington's disease mouse model","volume":"146","author":"Thomson","year":"2023","journal-title":"Brain."},{"key":"10.1016\/j.ymthe.2026.04.038_bib22","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1038\/gt.2017.71","article-title":"AAV5-miHTT gene therapy demonstrates suppression of mutant huntingtin aggregation and neuronal dysfunction in a rat model of Huntington's disease","volume":"24","author":"Miniarikova","year":"2017","journal-title":"Gene Ther."},{"key":"10.1016\/j.ymthe.2026.04.038_bib23","doi-asserted-by":"crossref","first-page":"2163","DOI":"10.1016\/j.ymthe.2018.06.021","article-title":"AAV5-miHTT gene therapy demonstrates broad distribution and strong human mutant huntingtin lowering in a Huntington's disease minipig model","volume":"26","author":"Evers","year":"2018","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2026.04.038_bib24","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1016\/j.omtm.2019.03.002","article-title":"AAV5-miHTT gene therapy demonstrates sustained huntingtin lowering and functional improvement in Huntington disease mouse models","volume":"13","author":"Spronck","year":"2019","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"10.1016\/j.ymthe.2026.04.038_bib25","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1126\/science.1225829","article-title":"A programmable dual-RNA\u2013guided DNA endonuclease in adaptive bacterial immunity","volume":"337","author":"Jinek","year":"2012","journal-title":"Science"},{"key":"10.1016\/j.ymthe.2026.04.038_bib26","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1126\/science.1231143","article-title":"Multiplex genome engineering using CRISPR\/Cas systems","volume":"339","author":"Cong","year":"2013","journal-title":"Science"},{"key":"10.1016\/j.ymthe.2026.04.038_bib27","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1126\/science.1232033","article-title":"RNA-guided human genome engineering via Cas9","volume":"339","author":"Mali","year":"2013","journal-title":"Science"},{"key":"10.1016\/j.ymthe.2026.04.038_bib28","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1146\/annurev.biochem.052308.093131","article-title":"The mechanism of double-strand DNA break repair by the nonhomologous DNA end-joining pathway","volume":"79","author":"Lieber","year":"2010","journal-title":"Annu. Rev. Biochem."},{"key":"10.1016\/j.ymthe.2026.04.038_bib29","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1093\/genetics\/161.3.1169","article-title":"Targeted chromosomal cleavage and mutagenesis in Drosophila using zinc-finger nucleases","volume":"161","author":"Bibikova","year":"2002","journal-title":"Genetics"},{"key":"10.1016\/j.ymthe.2026.04.038_bib30","doi-asserted-by":"crossref","first-page":"5809","DOI":"10.1073\/pnas.0800940105","article-title":"Targeted gene knockout in mammalian cells by using engineered zinc-finger nucleases","volume":"105","author":"Santiago","year":"2008","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.ymthe.2026.04.038_bib31","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1016\/j.omtn.2019.07.009","article-title":"CRISPR-Cas9-mediated genome editing increases lifespan and improves motor deficits in a Huntington's disease mouse model","volume":"17","author":"Ekman","year":"2019","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"10.1016\/j.ymthe.2026.04.038_bib32","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.141042","article-title":"Allele-specific silencing of the gain-of-function mutation in Huntington's disease using CRISPR\/Cas9","volume":"7","author":"Shin","year":"2022","journal-title":"JCI Insight"},{"key":"10.1016\/j.ymthe.2026.04.038_bib33","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.ymthe.2016.11.010","article-title":"CRISPR\/Cas9 editing of the mutant huntingtin allele in vitro and in vivo","volume":"25","author":"Monteys","year":"2017","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2026.04.038_bib34","doi-asserted-by":"crossref","first-page":"1759","DOI":"10.1038\/mt.2015.128","article-title":"Huntingtin haplotypes provide prioritized target panels for allele-specific silencing in Huntington sisease patients of European ancestry","volume":"23","author":"Kay","year":"2015","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2026.04.038_bib35","doi-asserted-by":"crossref","first-page":"5802","DOI":"10.1038\/s41467-022-33061-x","article-title":"Chemical engineering of therapeutic siRNAs for allele-specific gene silencing in Huntington's disease models","volume":"13","author":"Conroy","year":"2022","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ymthe.2026.04.038_bib36","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0099341","article-title":"Allele-specific silencing of mutant huntingtin in rodent brain and human stem cells","volume":"9","author":"Drouet","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.ymthe.2026.04.038_bib37","doi-asserted-by":"crossref","first-page":"2178","DOI":"10.1038\/mt.2011.201","article-title":"Potent and selective antisense oligonucleotides targeting single-nucleotide polymorphisms in the Huntington disease gene\/allele-specific silencing of mutant huntingtin","volume":"19","author":"Carroll","year":"2011","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2026.04.038_bib38","doi-asserted-by":"crossref","first-page":"2093","DOI":"10.1038\/mt.2014.153","article-title":"In vivo evaluation of candidate allele-specific mutant huntingtin gene silencing antisense oligonucleotides","volume":"22","author":"Southwell","year":"2014","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2026.04.038_bib39","doi-asserted-by":"crossref","DOI":"10.1038\/mtna.2015.7","article-title":"Artificial miRNAs targeting mutant huntingtin show preferential silencing in vitro and in vivo","volume":"4","author":"Monteys","year":"2015","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"10.1016\/j.ymthe.2026.04.038_bib40","doi-asserted-by":"crossref","DOI":"10.1016\/j.omtn.2024.102246","article-title":"Preclinical evaluation of stereopure antisense oligonucleotides for allele-selective lowering of mutant HTT","volume":"35","author":"Iwamoto","year":"2024","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"10.1016\/j.ymthe.2026.04.038_bib41","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1016\/j.omtn.2022.04.031","article-title":"A CAG repeat-targeting artificial miRNA lowers the mutant huntingtin level in the YAC128 model of Huntington's disease","volume":"28","author":"Kotowska-Zimmer","year":"2022","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"10.1016\/j.ymthe.2026.04.038_bib42","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1038\/s41591-018-0049-z","article-title":"CRISPR-Cas9 genome editing induces a p53-mediated DNA damage response","volume":"24","author":"Haapaniemi","year":"2018","journal-title":"Nat. Med"},{"key":"10.1016\/j.ymthe.2026.04.038_bib43","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1038\/s41591-018-0050-6","article-title":"p53 inhibits CRISPR-Cas9 engineering in human pluripotent stem cells","volume":"24","author":"Ihry","year":"2018","journal-title":"Nat. Med"},{"key":"10.1016\/j.ymthe.2026.04.038_bib44","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1038\/nbt.4192","article-title":"Repair of double-strand breaks induced by CRISPR-Cas9 leads to large deletions and complex rearrangements","volume":"36","author":"Kosicki","year":"2018","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.ymthe.2026.04.038_bib45","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1038\/s41467-019-09006-2","article-title":"CRISPR-Cas9 genome editing induces megabase-scale chromosomal truncations","volume":"10","author":"Cullot","year":"2019","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ymthe.2026.04.038_bib46","doi-asserted-by":"crossref","first-page":"4922","DOI":"10.1038\/s41467-021-25190-6","article-title":"CRISPR-Cas9 globin editing can induce megabase-scale copy-neutral losses of heterozygosity in hematopoietic cells","volume":"12","author":"Boutin","year":"2021","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ymthe.2026.04.038_bib47","doi-asserted-by":"crossref","first-page":"4439","DOI":"10.1038\/s41467-019-12449-2","article-title":"High levels of AAV vector integration into CRISPR-induced DNA breaks","volume":"10","author":"Hanlon","year":"2019","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ymthe.2026.04.038_bib48","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1016\/j.ymthe.2023.01.004","article-title":"Targeted long-read sequencing captures CRISPR editing and AAV integration outcomes in brain","volume":"31","author":"Simpson","year":"2023","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2026.04.038_bib49","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1038\/nature14299","article-title":"In vivo genome editing using Staphylococcus aureus Cas9","volume":"520","author":"Ran","year":"2015","journal-title":"Nature"},{"key":"10.1016\/j.ymthe.2026.04.038_bib50","article-title":"Enhanced CRISPR-Cas9 correction of Duchenne muscular dystrophy in mice by a self-complementary AAV delivery system","volume":"6","author":"Zhang","year":"2020","journal-title":"Sci. Adv."},{"key":"10.1016\/j.ymthe.2026.04.038_bib51","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1038\/nbt.3404","article-title":"Broadening the targeting range of Staphylococcus aureus CRISPR-Cas9 by modifying PAM recognition","volume":"33","author":"Kleinstiver","year":"2015","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.ymthe.2026.04.038_bib52","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1126\/science.aas9129","article-title":"Engineered CRISPR-Cas9 nuclease with expanded targeting space","volume":"361","author":"Nishimasu","year":"2018","journal-title":"Science"},{"key":"10.1016\/j.ymthe.2026.04.038_bib53","doi-asserted-by":"crossref","first-page":"13986","DOI":"10.1073\/pnas.0906463106","article-title":"Accumulation of ubiquitin conjugates in a polyglutamine disease model occurs without global ubiquitin\/proteasome system impairment","volume":"106","author":"Maynard","year":"2009","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.ymthe.2026.04.038_bib54","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1126\/science.aad5227","article-title":"Rationally engineered Cas9 nucleases with improved specificity","volume":"351","author":"Slaymaker","year":"2016","journal-title":"Science"},{"key":"10.1016\/j.ymthe.2026.04.038_bib55","doi-asserted-by":"crossref","first-page":"20969","DOI":"10.1073\/pnas.1906843116","article-title":"Rationally engineered Staphylococcus aureus Cas9 nucleases with high genome-wide specificity","volume":"116","author":"Tan","year":"2019","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.ymthe.2026.04.038_bib56","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1038\/nature16526","article-title":"High-fidelity CRISPR-Cas9 nucleases with no detectable genome-wide off-target effects","volume":"529","author":"Kleinstiver","year":"2016","journal-title":"Nature"},{"key":"10.1016\/j.ymthe.2026.04.038_bib57","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1016\/j.molcel.2020.02.023","article-title":"Highly parallel profiling of Cas9 variant specificity","volume":"78","author":"Schmid-Burgk","year":"2020","journal-title":"Mol. Cell"},{"key":"10.1016\/j.ymthe.2026.04.038_bib58","doi-asserted-by":"crossref","first-page":"75","DOI":"10.3389\/fnins.2018.00075","article-title":"Precise excision of the CAG tract from the huntingtin gene by Cas9 nickases","volume":"12","author":"Dabrowska","year":"2018","journal-title":"Front. Neurosci."},{"key":"10.1016\/j.ymthe.2026.04.038_bib59","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1186\/s12896-016-0250-4","article-title":"Death receptor-based enrichment of Cas9-expressing cells","volume":"16","author":"Liesche","year":"2016","journal-title":"BMC Biotechnol."},{"key":"10.1016\/j.ymthe.2026.04.038_bib60","doi-asserted-by":"crossref","first-page":"3619","DOI":"10.1016\/j.ymthe.2022.08.008","article-title":"CRISPR base editing of cis-regulatory elements enables the perturbation of neurodegeneration-linked genes","volume":"30","author":"Lim","year":"2022","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2026.04.038_bib61","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1089\/hyb.2005.24.231","article-title":"Epitope mapping of monoclonal antibody 4C8 recognizing the protein huntingtin","volume":"24","author":"Cong","year":"2005","journal-title":"Hybridoma"},{"key":"10.1016\/j.ymthe.2026.04.038_bib62","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1038\/nmeth.3284","article-title":"Digenome-seq: genome-wide profiling of CRISPR-Cas9 off-target effects in human cells","volume":"12","author":"Kim","year":"2015","journal-title":"Nat. Methods"},{"key":"10.1016\/j.ymthe.2026.04.038_bib63","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1016\/S0092-8674(00)81369-0","article-title":"Exon 1 of the HD gene with an expanded CAG repeat is sufficient to cause a progressive neurological phenotype in transgenic mice","volume":"87","author":"Mangiarini","year":"1996","journal-title":"Cell"},{"key":"10.1016\/j.ymthe.2026.04.038_bib64","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1093\/brain\/awr333","article-title":"Six-month partial suppression of Huntingtin is well tolerated in the adult rhesus striatum","volume":"135","author":"Grondin","year":"2012","journal-title":"Brain."},{"key":"10.1016\/j.ymthe.2026.04.038_bib65","doi-asserted-by":"crossref","DOI":"10.1093\/braincomms\/fcad344","article-title":"Revisiting the outcome of adult wild-type Htt inactivation in the context of HTT-lowering strategies for Huntington's disease","volume":"5","author":"Regio","year":"2023","journal-title":"Brain Commun."},{"key":"10.1016\/j.ymthe.2026.04.038_bib66","first-page":"3","article-title":"The effects of huntingtin-lowering: what do we know so far?","volume":"9","author":"Kaemmerer","year":"2019","journal-title":"Degener. Neurol. Neuromuscul. Dis."},{"key":"10.1016\/j.ymthe.2026.04.038_bib67","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1002\/ana.21569","article-title":"Sustained effects of nonallele-specific Huntingtin silencing","volume":"65","author":"Drouet","year":"2009","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.ymthe.2026.04.038_bib68","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pgen.1006846","article-title":"Elimination of huntingtin in the adult mouse leads to progressive behavioral deficits, bilateral thalamic calcification, and altered brain iron homeostasis","volume":"13","author":"Dietrich","year":"2017","journal-title":"Plos Genet."},{"key":"10.1016\/j.ymthe.2026.04.038_bib69","doi-asserted-by":"crossref","DOI":"10.26508\/lsa.202402571","article-title":"Global huntingtin knockout in adult mice leads to fatal neurodegeneration that spares the pancreas","volume":"7","author":"Bragg","year":"2024","journal-title":"Life Sci. Alliance"},{"key":"10.1016\/j.ymthe.2026.04.038_bib70","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1038\/mt.2009.286","article-title":"Comparative transduction efficiency of AAV vector serotypes 1-6 in the substantia nigra and striatum of the primate brain","volume":"18","author":"Markakis","year":"2010","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2026.04.038_bib71","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0076310","article-title":"Analysis of transduction efficiency, tropism and axonal transport of AAV serotypes 1, 2, 5, 6, 8 and 9 in the mouse brain","volume":"8","author":"Aschauer","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.ymthe.2026.04.038_bib72","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1038\/s41434-020-0178-0","article-title":"Transduction patterns in the CNS following various routes of AAV-5-mediated gene delivery","volume":"28","author":"Pietersz","year":"2021","journal-title":"Gene Ther."},{"key":"10.1016\/j.ymthe.2026.04.038_bib73","doi-asserted-by":"crossref","first-page":"239","DOI":"10.3233\/JHD-160215","article-title":"Cellular analysis of silencing the Huntington's disease gene using AAV9 mediated delivery of artificial micro RNA into the striatum of Q140\/Q140 mice","volume":"5","author":"Keeler","year":"2016","journal-title":"J. Huntingtons Dis."},{"key":"10.1016\/j.ymthe.2026.04.038_bib74","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2022.1051559","article-title":"Kinetics and durability of transgene expression after intrastriatal injection of AAV9 vectors","volume":"13","author":"Hollidge","year":"2022","journal-title":"Front. Neurol."},{"key":"10.1016\/j.ymthe.2026.04.038_bib75","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1016\/j.omtm.2023.05.001","article-title":"An AAV capsid increases transduction of striatum and a ChAT promoter allows selective cholinergic neuron transduction","volume":"29","author":"Santoscoy","year":"2023","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"10.1016\/j.ymthe.2026.04.038_bib76","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1177\/10430342251359955","article-title":"Intrastriatal delivery of a zinc finger protein targeting the mutant HTT gene allele obviates lipid phenotypes in brain and plasma in Huntington's disease mice","volume":"36","author":"Iwanowicz","year":"2025","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.ymthe.2026.04.038_bib77","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2022.111953","article-title":"Neuronal and astrocytic contributions to Huntington's disease dissected with zinc finger protein transcriptional repressors","volume":"42","author":"Gangwani","year":"2023","journal-title":"Cell Rep."},{"key":"10.1016\/j.ymthe.2026.04.038_bib78","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1038\/sj.gt.3301905","article-title":"Human synapsin 1 gene promoter confers highly neuron-specific long-term transgene expression from an adenoviral vector in the adult rat brain depending on the transduced area","volume":"10","author":"K\u00fcgler","year":"2003","journal-title":"Gene Ther."},{"key":"10.1016\/j.ymthe.2026.04.038_bib79","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1021\/acschemneuro.6b00374","article-title":"Neurocytometry: flow cytometric sorting of specific neuronal populations from human and rodent brain","volume":"8","author":"Martin","year":"2017","journal-title":"ACS Chem. Neurosci."},{"key":"10.1016\/j.ymthe.2026.04.038_bib80","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1038\/s41551-019-0501-5","article-title":"Cytosine and adenine base editing of the brain, liver, retina, heart and skeletal muscle of mice via adeno-associated viruses","volume":"4","author":"Levy","year":"2020","journal-title":"Nat. Biomed. Eng."},{"key":"10.1016\/j.ymthe.2026.04.038_bib81","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1038\/s41467-024-55548-5","article-title":"A high-fidelity CRISPR-Cas13 system improves abnormalities associated with C9ORF72-linked ALS\/FTD","volume":"16","author":"Mccallister","year":"2025","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ymthe.2026.04.038_bib82","doi-asserted-by":"crossref","first-page":"321","DOI":"10.3233\/JHD-180329","article-title":"Longitudinal biochemical assay analysis of mutant huntingtin exon 1 protein in R6\/2 mice","volume":"7","author":"Morozko","year":"2018","journal-title":"J. Huntingtons Dis."},{"key":"10.1016\/j.ymthe.2026.04.038_bib83","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1083\/jcb.200710158","article-title":"Suppression of neuropil aggregates and neurological symptoms by an intracellular antibody implicates the cytoplasmic toxicity of mutant huntingtin","volume":"181","author":"Wang","year":"2008","journal-title":"J. Cell Biol."},{"key":"10.1016\/j.ymthe.2026.04.038_bib84","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.1093\/hmg\/ddg169","article-title":"Selective striatal neuronal loss in a YAC128 mouse model of Huntington disease","volume":"12","author":"Slow","year":"2003","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.ymthe.2026.04.038_bib85","doi-asserted-by":"crossref","first-page":"3823","DOI":"10.1093\/hmg\/ddi407","article-title":"Selective degeneration and nuclear localization of mutant huntingtin in the YAC128 mouse model of Huntington disease","volume":"14","author":"Van Raamsdonk","year":"2005","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.ymthe.2026.04.038_bib86","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/S0896-6273(00)80764-3","article-title":"A YAC mouse model for Huntington's disease with full-length mutant huntingtin, cytoplasmic toxicity, and selective striatal neurodegeneration","volume":"23","author":"Hodgson","year":"1999","journal-title":"Neuron"},{"key":"10.1016\/j.ymthe.2026.04.038_bib87","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.nbd.2019.04.015","article-title":"Astrocyte transduction is required for rescue of behavioral phenotypes in the YAC128 mouse model with AAV-RNAi mediated HTT lowering therapeutics","volume":"129","author":"Stanek","year":"2019","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.ymthe.2026.04.038_bib88","doi-asserted-by":"crossref","first-page":"258","DOI":"10.3389\/fnmol.2019.00258","article-title":"The role of microglia and astrocytes in Huntington's disease","volume":"12","author":"Palpagama","year":"2019","journal-title":"Front. Mol. Neurosci."},{"key":"10.1016\/j.ymthe.2026.04.038_bib89","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1089\/hum.2010.245","article-title":"Optimizing promoters for recombinant adeno-associated virus-mediated gene expression in the peripheral and central nervous system using self-complementary vectors","volume":"22","author":"Gray","year":"2011","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.ymthe.2026.04.038_bib90","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.abk2485","article-title":"Targeted gene silencing in the nervous system with CRISPR-Cas13","volume":"8","author":"Powell","year":"2022","journal-title":"Sci. Adv."},{"key":"10.1016\/j.ymthe.2026.04.038_bib91","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1016\/j.ymthe.2020.01.005","article-title":"Treatment of a mouse model of ALS by in vivo base editing","volume":"28","author":"Lim","year":"2020","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2026.04.038_bib92","doi-asserted-by":"crossref","first-page":"2125","DOI":"10.1093\/hmg\/ddy119","article-title":"A whole brain longitudinal study in the YAC128 mouse model of Huntington's disease shows distinct trajectories of neurochemical, structural connectivity and volumetric changes","volume":"27","author":"Petrella","year":"2018","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.ymthe.2026.04.038_bib93","doi-asserted-by":"crossref","first-page":"2738","DOI":"10.1093\/hmg\/ddn175","article-title":"Accumulation of N-terminal mutant huntingtin in mouse and monkey models implicated as a pathogenic mechanism in Huntington's disease","volume":"17","author":"Wang","year":"2008","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.ymthe.2026.04.038_bib94","doi-asserted-by":"crossref","first-page":"4862","DOI":"10.1093\/hmg\/ddv209","article-title":"Oxidative metabolism in YAC128 mouse model of Huntington's disease","volume":"24","author":"Hamilton","year":"2015","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.ymthe.2026.04.038_bib95","first-page":"1115","article-title":"A novel humanized mouse model of Huntington disease for preclinical development of therapeutics targeting mutant huntingtin alleles","volume":"26","author":"Southwell","year":"2017","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.ymthe.2026.04.038_bib96","first-page":"36","article-title":"Potent and sustained huntingtin lowering via AAV5 encoding miRNA preserves striatal volume and cognitive function in a humanized mouse model of Huntington disease","volume":"48","author":"Caron","year":"2020","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.ymthe.2026.04.038_bib97","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/978-3-319-71779-1_1","article-title":"Clinical features of Huntington\u2019s disease","volume":"1049","author":"Ghosh","year":"2018","journal-title":"Adv. Exp. Med. Biol."},{"key":"10.1016\/j.ymthe.2026.04.038_bib98","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1093\/hmg\/ddl440","article-title":"The first 17 amino acids of Huntingtin modulate its sub-cellular localization, aggregation and effects on calcium homeostasis","volume":"16","author":"Rockabrand","year":"2007","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.ymthe.2026.04.038_bib99","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1016\/j.neuron.2016.02.003","article-title":"The biology of huntingtin","volume":"89","author":"Saudou","year":"2016","journal-title":"Neuron"},{"key":"10.1016\/j.ymthe.2026.04.038_bib100","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1016\/0092-8674(95)90542-1","article-title":"Targeted disruption of the Huntington's disease gene results in embryonic lethality and behavioral and morphological changes in heterozygotes","volume":"81","author":"Nasir","year":"1995","journal-title":"Cell"},{"key":"10.1016\/j.ymthe.2026.04.038_bib101","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1126\/science.7618107","article-title":"Inactivation of the mouse Huntington's disease gene homolog Hdh","volume":"269","author":"Duyao","year":"1995","journal-title":"Science"},{"key":"10.1016\/j.ymthe.2026.04.038_bib102","doi-asserted-by":"crossref","first-page":"2307","DOI":"10.1056\/NEJMoa1900907","article-title":"Targeting huntingtin expression in patients with Huntington's disease","volume":"380","author":"Tabrizi","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ymthe.2026.04.038_bib103","doi-asserted-by":"crossref","first-page":"2203","DOI":"10.1056\/NEJMc2300400","article-title":"Tominersen in adults with manifest Huntington's disease","volume":"389","author":"Mccolgan","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ymthe.2026.04.038_bib104","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.abb8920","article-title":"Widespread and sustained target engagement in Huntington's disease minipigs upon intrastriatal microRNA-based gene therapy","volume":"13","author":"Vall\u00e8s","year":"2021","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.ymthe.2026.04.038_bib105","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.arr.2015.04.004","article-title":"Genetics and molecular biology of brain calcification","volume":"22","author":"Deng","year":"2015","journal-title":"Ageing Res. Rev."},{"key":"10.1016\/j.ymthe.2026.04.038_bib106","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2307796121","article-title":"Targeted nonviral delivery of genome editors in vivo","volume":"121","author":"Tsuchida","year":"2024","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.ymthe.2026.04.038_bib107","doi-asserted-by":"crossref","first-page":"2719","DOI":"10.1172\/JCI92087","article-title":"CRISPR\/Cas9-mediated gene editing ameliorates neurotoxicity in mouse model of Huntington's disease","volume":"127","author":"Yang","year":"2017","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.ymthe.2026.04.038_bib108","first-page":"4566","article-title":"Permanent inactivation of Huntington's disease mutation by personalized allele-specific CRISPR\/Cas9","volume":"25","author":"Shin","year":"2016","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.ymthe.2026.04.038_bib109","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1016\/j.omtm.2022.08.005","article-title":"PAM-altering SNP-based allele-specific CRISPR-Cas9 therapeutic strategies for Huntington's disease","volume":"26","author":"Shin","year":"2022","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"10.1016\/j.ymthe.2026.04.038_bib110","doi-asserted-by":"crossref","first-page":"2980","DOI":"10.1016\/j.celrep.2017.08.075","article-title":"The self-inactivating KamiCas9 system for the editing of CNS disease genes","volume":"20","author":"Merienne","year":"2017","journal-title":"Cell Rep."},{"key":"10.1016\/j.ymthe.2026.04.038_bib111","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1038\/s42003-023-04829-8","article-title":"DNA double-strand break-free CRISPR interference delays Huntington's disease progression in mice","volume":"6","author":"Seo","year":"2023","journal-title":"Commun. Biol."},{"key":"10.1016\/j.ymthe.2026.04.038_bib112","doi-asserted-by":"crossref","first-page":"4714","DOI":"10.1016\/j.ymthe.2025.06.045","article-title":"Peeling back the layers of immunogenicity in Cas9-based genomic medicine","volume":"33","author":"Stigzelius","year":"2025","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2026.04.038_bib113","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1016\/j.tibtech.2020.10.010","article-title":"Next-generation CRISPR technologies and their applications in gene and cell therapy","volume":"39","author":"Zeballos C","year":"2021","journal-title":"Trends Biotechnol."},{"key":"10.1016\/j.ymthe.2026.04.038_bib114","article-title":"In vivo CRISPR base editing for treatment of Huntington's disease","author":"Shirguppe","year":"2024","journal-title":"bioRxiv"},{"key":"10.1016\/j.ymthe.2026.04.038_bib115","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.89782.2","article-title":"Base editing strategies to convert CAG to CAA diminish the disease-causing mutation in Huntington's disease","volume":"12","author":"Choi","year":"2024","journal-title":"Elife"},{"key":"10.1016\/j.ymthe.2026.04.038_bib116","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1038\/s41588-025-02172-8","article-title":"Base editing of trinucleotide repeats that cause Huntington's disease and Friedreich's ataxia reduces somatic repeat expansions in patient cells and in mice","volume":"57","author":"Matuszek","year":"2025","journal-title":"Nat. Genet."},{"key":"10.1016\/j.ymthe.2026.04.038_bib117","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1038\/s41593-022-01207-1","article-title":"An RNA-targeting CRISPR-Cas13d system alleviates disease-related phenotypes in Huntington's disease models","volume":"26","author":"Morelli","year":"2023","journal-title":"Nat. Neurosci."},{"key":"10.1016\/j.ymthe.2026.04.038_bib118","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/s13024-024-00794-w","article-title":"RNA-Targeting CRISPR\/CasRx system relieves disease symptoms in Huntington's disease models","volume":"20","author":"Lin","year":"2025","journal-title":"Mol. Neurodegener."},{"key":"10.1016\/j.ymthe.2026.04.038_bib119","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1038\/s41586-019-1161-z","article-title":"Transcriptome-wide off-target RNA editing induced by CRISPR-guided DNA base editors","volume":"569","author":"Gr\u00fcnewald","year":"2019","journal-title":"Nature"},{"key":"10.1016\/j.ymthe.2026.04.038_bib120","doi-asserted-by":"crossref","DOI":"10.1093\/nar\/gkac159","article-title":"CRISPR\/Cas13 effectors have differing extents of off-target effects that limit their utility in eukaryotic cells","volume":"50","author":"Ai","year":"2022","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.ymthe.2026.04.038_bib121","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1038\/nbt.3583","article-title":"Analyzing CRISPR genome-editing experiments with CRISPResso","volume":"34","author":"Pinello","year":"2016","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.ymthe.2026.04.038_bib122","article-title":"Aligning sequence reads, clone sequences and assembly contigs with BWA-MEM","author":"Li","year":"2013","journal-title":"arXiv"},{"key":"10.1016\/j.ymthe.2026.04.038_bib123","doi-asserted-by":"crossref","first-page":"2078","DOI":"10.1093\/bioinformatics\/btp352","article-title":"The sequence alignment\/map format and SAMtools","volume":"25","author":"Li","year":"2009","journal-title":"Bioinformatics"},{"key":"10.1016\/j.ymthe.2026.04.038_bib124","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1093\/bioinformatics\/btv566","article-title":"Qualimap 2: advanced multi-sample quality control for high-throughput sequencing data","volume":"32","author":"Okonechnikov","year":"2016","journal-title":"Bioinformatics"},{"key":"10.1016\/j.ymthe.2026.04.038_bib125","doi-asserted-by":"crossref","first-page":"2204","DOI":"10.1093\/bioinformatics\/btq351","article-title":"BigWig and BigBed: enabling browsing of large distributed datasets","volume":"26","author":"Kent","year":"2010","journal-title":"Bioinformatics"},{"key":"10.1016\/j.ymthe.2026.04.038_bib126","doi-asserted-by":"crossref","first-page":"W187","DOI":"10.1093\/nar\/gku365","article-title":"deepTools: a flexible platform for exploring deep-sequencing data","volume":"42","author":"Ram\u00edrez","year":"2014","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.ymthe.2026.04.038_bib127","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.1038\/s41596-020-00453-6","article-title":"Identifying genome-wide off-target sites of CRISPR RNA-guided nucleases and deaminases with Digenome-seq","volume":"16","author":"Kim","year":"2021","journal-title":"Nat. Protoc."}],"container-title":["Molecular Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525001626003035?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525001626003035?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T03:28:12Z","timestamp":1786073292000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1525001626003035"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":127,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["S1525001626003035"],"URL":"https:\/\/doi.org\/10.1016\/j.ymthe.2026.04.038","relation":{"has-preprint":[{"id-type":"doi","id":"10.64898\/2025.12.20.695720","asserted-by":"object"}]},"ISSN":["1525-0016"],"issn-type":[{"value":"1525-0016","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Treatment of Huntington\u2019s disease with a pan-HTT-targeting CRISPR nuclease","name":"articletitle","label":"Article Title"},{"value":"Molecular Therapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ymthe.2026.04.038","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Inc. on behalf of The American Society of Gene and Cell Therapy.","name":"copyright","label":"Copyright"}]}}